BioSpace News Archive

Deals

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year

January 10, 2021
·
15 min read
Biotech Bay

Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference

Atara has had productive interactions with the FDA for ATA188 and is progressing the Phase 2 randomized clinical trial (RCT) toward an interim analysis in H1 2022

January 10, 2021
·
7 min read
Drug Development

BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

Significantly Reduced Mean Annualized Bleeding Rate by 84% (p-value <0.0001) Demonstrating Superiority to Factor VIII Prophylaxis, and Reduced Mean Annualized Factor VIII Infusion Rate by 99% (p-value <0.0001)

January 10, 2021
·
14 min read
Biotech Beach

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

Hutchison China MediTech Limited and Inmagene Biopharmaceuticals announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases.

January 10, 2021
·
4 min read
Kintor’s Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients

Kintor Pharmaceutical Limited is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients.

January 10, 2021
·
2 min read
BioMidwest

Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

Humanigen, Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S.

January 10, 2021
·
6 min read
Biotech Beach

Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference

Sorrento Therapeutics, Inc., announced that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference

January 10, 2021
·
4 min read
Drug Development

Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA.

On January 8, 2021, Shenzhen Chipscreen Biosciences Co., Ltd. submitted its pivotal phase III clinical trial application of national class I innovative drug Chiauranib to NMPA, for the treatment of Small Cell Lung Cancer as a single agent for the patients after 2nd-line systemic chemotherapy and recurrence afterwards.

January 10, 2021
·
4 min read